Contact this trialFirst, we need to learn more about you.
Akt/ERK Inhibitor
ONC201 + Paclitaxel for Ovarian Cancer
Recruiting1 awardPhase 2
Flint, Michigan
This trial is studying a combination of two drugs, ONC201 and paclitaxel, to see if they are effective in treating ovarian, fallopian tube, or primary peritoneal cancer that has returned or stopped responding to other treatments.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service